Chimeric Therapeutics Ltd
ASX:CHM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Chimeric Therapeutics Ltd
Other Current Assets
Chimeric Therapeutics Ltd
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chimeric Therapeutics Ltd
ASX:CHM
|
Other Current Assets
AU$131.4k
|
CAGR 3-Years
0%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Other Current Assets
$7.9m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
7%
|
|
|
CSL Ltd
ASX:CSL
|
Other Current Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Race Oncology Ltd
ASX:RAC
|
Other Current Assets
AU$255.3k
|
CAGR 3-Years
-26%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Other Current Assets
AU$16.1m
|
CAGR 3-Years
21%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Other Current Assets
AU$460.9k
|
CAGR 3-Years
19%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
Chimeric Therapeutics Ltd
Glance View
Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm's technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. The CAR T cell is an immune T cell taken from a patient’s blood which is sent to a lab where it is re-programmed to become a charged guided missile, to seek out a specific target on the surface of a cancer cell.
See Also
What is Chimeric Therapeutics Ltd's Other Current Assets?
Other Current Assets
131.4k
AUD
Based on the financial report for Jun 30, 2025, Chimeric Therapeutics Ltd's Other Current Assets amounts to 131.4k AUD.
What is Chimeric Therapeutics Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 3Y
0%
Over the last year, the Other Current Assets growth was 0%.
